The American Association of Cancer Research has joined the Cancer Therapy Research Center at the University of Texas Health Science Center at San Antonio, and the Baylor College of Medicine in putting on this year's San Antonio Breast Cancer Symposium.
Patient advocates lend a strong voice to this year’s San Antonio Breast Cancer Symposium.
A synopsis of last year's San Antonio Breast Cancer Symposium updates.
A look at the Triple Negative Breast Cancer Foundation’s roots and how the organization plans to expand their presence by funding necessary research and demanding that triple-negative breast cancer does not go unnoticed.
Advocate Joan Venticinque blogs about patient advocacy.
CURE publisher Susan McClure blogs from a survivor's perspective.
CURE Editor-in-Chief Debu Tripathy, MD, blogs on medical issues from SABCS.
Overview of education sessions during opening of SABCS.
New colorectal cancer screening gets high marks.
The validity of performing monthly breast self-exams to improve survival rates is again being questioned.
Controlling lymphedema with the old and the new.
Funding for lymphedema research is desperately needed.
Predicting drug response in colorectal cancer.
KRAS gene mutations are detected in various cancers, including colorectal.
A timeline of KRAS research.
Issues after surgery can be taxing for patient and caregiver.
Breast cancer survivors find a constructive outlet for their altruism.
Reduce breast cancer risk through diet and lifestyle.
Controversy surrounds lung cancer screening.
A personal recount of a long-term effect of breast cancer surgery.
A new clinical trial site for breast cancer patients.
A daughter fights the stigma of lung cancer in honor of her mother.
News updates from the American Society of Hematology and the San Antonio Breast Cancer Symposium.
Avastin is one of a new class of drugs that works by targeting the newly formed blood vessels that develop around tumors, a process called antiangiogenesis—recent studies have seen positive survival results in colon cancer and now lung cancer.
Women with hormone-negative breast cancers may not be able to benefit from tamoxifen and aromatase inhibitors, but a subset of patients with HER2-positive breast cancer are able to take advantage of advances such as Herceptin and Tykerb. For women with hormone- and HER2-negative cancers, or triple negative, new research into what drives these cancers and prevent recurrence may increase treatment options and benefit this population.
